🟢 Edesa Biotech is trading 8.17% up in pre-market — no clear catalyst identified

Edesa Biotech is trading at $2.78, up 8.17%, before the October 19 open, with no clear company-specific catalyst identified.

• The October 16 close was $2.57.
• Edesa Biotech’s FDA IND clearance for its Phase 2 vitiligo study was announced October 15, not October 19; topline data are anticipated in Q4 2027.
• Major U.S. indices are higher while the biotech sector is lower; these mixed signals do not establish a clear cause for the move.